There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
These are the top buyers of the scrapped electoral bonds, the data for which was released by the Election Commission on Thursday.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
A reading of the reports suggests that there is no standard practice for reporting political contributions and it is left to the company's discretion to report them as they find fit.
The BSE Healthcare Index is up 19 per cent as compared to BSE Sensex returns of 11 per cent during this period. Nitin Agarwal of DAM Capital highlighted this trend in a report last month. "After a sustained period of underperformance over FY21-23, the BSE Healthcare Index has once again captured the spotlight. "The recent uptick in performance has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with sustaining momentum in domestic branded formulations," he said.
The S&P BSE Sensex shed 119 points to close at 27,977 and the Nifty50 dropped 45 points to finish at 8,591.
While about 8,000 people are in the long list of invitees, the select list features just a few hundred people, including prominent politicians, leading industrialists, top film stars, sportspersons, bureaucrats and diplomats.
It also asked why the data shared pertained to a period from April 2019 even though the scheme for anonymous political funding was introduced in 2017.
From steel tycoon Lakshmi Mittal to billionaire Sunil Bharti Mittal's Airtel, Anil Agarwal's Vedanta, ITC, Mahindra and Mahindra, and a lesser-known Future Gaming and Hotel Services were among the prominent buyers of the now-scrapped electoral bonds for making political donations.
The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.
Future Gaming and Hotel Services whose director is the lottery magnate Santiago Martin is the top purchaser of electoral bonds having purchased bonds worth Rs 1,368, according to data uploaded by the Election Commission of India on its website on Thursday.
Which entrepreneur would willingly part with her or his hard-earned money for grasping, self-serving politicians? asks Debashis Basu.
Benchmark indices declined for the third day running on Tuesday, with the Sensex tumbling 567.98 points amid weak global markets and continuous foreign funds outflow. Investors were risk averse ahead of the RBI's policy decision on Wednesday, traders said. The 30-share BSE Sensex tanked 567.98 points or 1.02 per cent to settle at 55,107.34.
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.
NSE Nifty ended at 4,113, down 42 points.
Once available, Sputnik V will be the third vaccine to be used in India against coronavirus.
Equity benchmark indices ended lower on Thursday in line with weak global market trends. The 30-share BSE Sensex declined 230.12 points or 0.37 per cent to settle at 61,750.60. During the day, it fell 337.45 points or 0.54 per cent to 61,643.27.
The first phase of the programme will kick off with vaccinations in Hyderabad on Monday and in Visakhapatnam on Tuesday (May 18) at Apollo facilities.
Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.
Equity benchmarks ended higher on Wednesday amid buying in banking counters and a firm trend in global markets. Continuing its previous day rally, the 30-share BSE Sensex climbed 91.62 points or 0.15 per cent to settle at 61,510.58. During the day, it jumped 361.94 points or 0.58 per cent to 61,780.90. The broader NSE Nifty gained 23.05 points or 0.13 per cent to end at 18,267.25.
Markets continued to fall on Monday, with the Sensex declining 94 points as investors remained cautious amid unabated selling by foreign funds and elevated crude oil prices ahead of the RBI's policy decision later this week. The 30-share BSE Sensex declined 93.91 points or 0.17 per cent to end at 55,675.32. During the day, it tanked 473.49 points or 0.84 per cent to 55,295.74.
It has currently pared gains on weakness in select stocks, and is now up 22 points at 4,655. The Nifty has advanced 10 points to 1,488.
Benchmark indices ended the day in the negative territory on Tuesday amid weak global market trends and rising crude prices. Falling for the third day running, the 30-share BSE benchmark ended 208.24 points or 0.33 per cent lower at 62,626.36. During the day, it tumbled 444.53 points or 0.70 per cent to 62,390.07.
Equity benchmark indices ended on a flat note on Monday, with the BSE Sensex falling nearly 34 points, recording its second day of decline after an eight-day rally. In a volatile trade, the 30-share BSE benchmark dipped 33.9 points or 0.05 per cent to settle at 62,834.60. During the day, it fell 360.62 points or 0.57 per cent to 62,507.88.
Axis Bank was the top loser in the Sensex pack, shedding around 2 per cent, followed by Reliance Industries, Kotak Bank, Bharti Airtel, Titan, Dr Reddy's and M&M. NSE Nifty fell by 100.55 points to 17,898.65.
Benchmark indices ended in the green on Friday after falling for the past two days, helped by continuous buying from foreign institutional investors and a largely positive trend in Asian and European markets. The 30-share BSE Sensex climbed 113.95 points or 0.19 per cent to settle at 60,950.36. Similarly, the broader NSE Nifty ended 64.45 points or 0.36 per cent higher at 18,117.15.
Equity benchmarks bounced back sharply on Friday after facing a heavy drubbing in the previous trade, with the Sensex and Nifty jumping nearly 3 per cent, aided by positive trends from global markets and across-the-board buying. Index majors Reliance Industries and HDFC twins saw robust buying, helping the benchmarks. The 30-share BSE Sensex rallied 1,534.16 points or 2.91 per cent to settle at 54,326.39.
Benchmark indices maintained their winning momentum for the fourth day running on Tuesday, helped by a rally in Asian and European markets and continuous foreign fund inflows. The 30-share BSE Sensex climbed 374.76 points or 0.62 per cent to settle at 61,121.35. During the day, it jumped 543.14 points or 0.89 per cent to 61,289.73.
Equity benchmark indices ended the trade in the positive territory on Wednesday, with the BSE Sensex closing at its fresh life-time high of 61,980.72, helped by buying in banking counters. After facing highs and lows during the day, the 30-share BSE Sensex finally ended 107.73 points or 0.17 per cent higher at 61,980.72. During the day, the index hit its 52-week high of 62,052.57, higher by 179.58 points.
Equity benchmark Sensex climbed 248 points to close at its all-time high on Tuesday, tracking unabated foreign capital inflows amid a positive trend in global markets. After a see-saw session, the 30-share BSE Sensex climbed 248.84 points or 0.40 per cent to settle at 61,872.99 -- surpassing its previous closing peak of 61,795.04 on November 11. During the day, the index witnessed a high of 61,955.96 and a low of 61,436.90.
BSE benchmark Sensex plummeted 778 points to close below the 55,500-level on Wednesday following a broad-based selloff in global markets as the Russia-Ukraine crisis escalated. The 30-share BSE index ended 778.38 points or 1.38 per cent lower at 55,468.90. Similarly, the NSE Nifty plunged 187.95 points or 1.12 per cent to 16,605.95.
Benchmark indices ended lower on Wednesday after a four-day rally amid a mixed trend in global equity markets. After a positive beginning, the 30-share BSE Sensex failed to hold on to the gains and ended 215.26 points or 0.35 per cent lower at 60,906.09. During the day, it slipped 326.96 points or 0.53 per cent to 60,794.39.
According to the recommendations of the Subject Expert Committee (SEC) meeting held on July 30, which have been approved by the Drugs Controller General of India (DCGI), Sputnik-Light is the same as the component-1 of Sputnik V and as its safety and immunogenicity data in the Indian population has already been generated in a trial here, there seems to be inadequate data and justification for conducting a separate, similar trial.
Russian COVID-19 vaccine Sputnik V vaccine will be available in nine more cities across India, including Bengaluru, Mumbai, Chennai, Visakhapatnam, Baddi, Kolhapur and Miryalaguda, informed the official twitter handle of Sputnik V.
Benchmark BSE Sensex rallied over 350 points on Tuesday following gains in index majors HDFC twins, Bharti Airtel and Infosys amid a largely positive trend in global equity markets. The 30-share BSE barometer jumped 350.16 points or 0.61 per cent to settle at 57,943.65. During the day, it rallied 408.04 points or 0.70 per cent to 58,001.53. The broader NSE Nifty gained 103.30 points or 0.60 per cent to settle at 17,325.30.
Benchmark indices Sensex and Nifty rebounded nearly 1 per cent on Wednesday, snapping their three-day losing run following gains in banking, power and IT shares amid positive trends in European markets. The 30-share BSE barometer climbed 478.59 points or 0.84 per cent to settle at 57,625.91. During the day, it jumped 540.32 points or 0.94 per cent to 57,687.64.
Dr Reddy's Laboratories is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of Sputnik V in India.
Asian Paints was the top loser in the Sensex pack, tanking around 5 per cent, followed by Reliance Industries, Infosys, Tata Steel, TCS and Dr Reddy's.
Equity benchmarks Sensex and Nifty settled on a positive note on Thursday, helped by buying in metal and realty stocks amid mixed global market trends. The 30-share BSE benchmark climbed 212.88 points or 0.36 per cent to settle at 59,756.84. During the day, it jumped 415.98 points or 0.69 per cent to 59,959.94. On similar lines, the broader NSE Nifty advanced 80.60 points or 0.46 per cent to end at 17,736.95.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances